Osimertinib plus chemotherapy shows superior results versus osimertinib alone for EGFR-mutated advanced lung cancer

Share :
Published: 21 Sep 2023
Views: 166
Prof Pasi Janne - Dana Farber Cancer Institute, Boston, USA

Prof Pasi Janne speaks to ecancer about the FLAURA2 study presented at WCLC 2023.

He explains the study enrolled 557 patients and randomised them 1:1 into two treatment arms: osimertinib plus chemotherapy or osimertinib monotherapy.The combination arm involved a regimen of osimertinib (80 mg daily) alongside pemetrexed and either cisplatin or carboplatin.

The results showed a hazard ratio of 0.62 (95% CI 0.49, 0.79; p<0.0001) for progression-free survival, signifying an 8.8-month enhancement in median progression-free survival.

Therefore, osimertinib plus chemotherapy demonstrated superior results than osimertinib alone for patients with EGFR-mutated advanced lung cancer. 

Read the full news story here